Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.57 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.43 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL694 | 1.00 | MEN1 (1.00) | MEN1KMT2ALOXLOXL3LOXL2 | |
| Fumaric Acid SCHEMBL28115011 | 1.00 | MEN1 (1.00) | MEN1KMT2ALOXLOXL3LOXL2 | |
| Bicarbonate SCHEMBL909963 | 0.85 | — | — | |
| Bicarbonate SCHEMBL28678945 | 0.85 | KMT2A (0.73) | MEN1KMT2ALOXLOXL3LOXL2 | |
| Oxalic Acid SCHEMBL11876639 | 0.82 | KMT2A (0.70) | MEN1KMT2ALOXLOXL3LOXL2 | |
| Carbamic Acid SCHEMBL28684032 | 0.82 | — | — | |
| Formic Acid SCHEMBL7409232 | 0.77 | — | — | |
| Propionic Acid SCHEMBL28712838 | 0.76 | KMT2A (0.61) | MEN1KMT2ALOXLOXL3LOXL2 | |
| Beta-Alanine SCHEMBL28248711 | 0.76 | KMT2A (0.61) | MEN1KMT2ALOXLOXL3LOXL2 | |
| Fumaric Acid SCHEMBL786567 | 0.76 | TSHR (0.64) | MEN1KMT2ATSHRTP53EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 778 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180199577-A1 | COMPOSITIONS FOR CONTROL OF HEMIPTERAN INSECT STYLET SHEATH STRUCTURE FORMATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2018-07-19 | — | — | US | claimed |
| US-9949489-B2 | Methods for control of hemipteran insect stylet sheath structure formation | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2018-04-24 | — | — | US | claimed |
| WO-2016176061-A1 | COMPOSITIONS AND METHODS FOR CONTROL OF HEMIPTERAN INSECT STYLET SHEATH STRUCTURE FORMATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2016-11-03 | — | — | WO | claimed |
| US-20160316762-A1 | COMPOSITIONS AND METHODS FOR CONTROL OF HEMIPTERAN INSECT STYLET SHEATH STRUCTURE FORMATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2016-11-03 | — | — | US | claimed |
| US-7109377-B2 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-09-19 | — | — | US | claimed |
| US-20030082830-A1 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-01 | — | — | US | claimed |
| US-6448443-B1 | GENERATED FROM DIVERSIFIABLE SCAFFOLDS SYNTHESIZED FROM THE PYRIDINE-BASED TEMPLATE ISONICOTINAMIDE; ALSO PROVIDES A NOVEL ORTHO-NITROBENZYL PHOTOLINKER; SYNTHESIZED FROM A SHIKIMIC ACID BASED EPOXYOL TEMPLATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-09-10 | — | — | US | claimed |
| WO-2000006525-A9 | SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS | HARVARD COLLEGE (US) | 2000-04-20 | — | — | WO | claimed |
| WO-2000006525-A2 | SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-02-10 | — | — | WO | claimed |
| EP-3325513-B1 | ANTI-PD-L1 ANTIBODIES AND USES THEREOF | I MAB BIOPHARMA CO LTD (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116987-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-5098926-A | Antitumor agents | UNIVERSITY PATENTS, INC. (US) | 1992-03-24 | — | — | US | disclosed |
| US-4981933-A | Azlactone copolymers | POLAROID CORPORATION (US) | 1991-01-01 | — | — | US | disclosed |
| US-4888341-A | 6-substituted mitomycin analogs | UNIVERSITY PATENTS, INC. (US) | 1989-12-19 | — | — | US | disclosed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | disclosed |
| US-4485088-A | INHIBITION OF ABNORMAL SCAR FORMATION | BIO-PRODUCTS, INC. (US) | 1984-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116987-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | CCR8, VSIG8, CCR3 | MEN1 3102/4885KMT2A 1565/4885SLC6A2 3195/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | MEN1 1486/4885KMT2A 94/4885SLC6A2 4404/4885 |
| US-20030082830-A1 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | TKFC, NISCH, PTGIS | MEN1 4825/4885KMT2A 1022/4885SLC6A2 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.